Caption Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.7M Buy
1,525,300
+1,212,800
+388% +$19.1M 0.08% 268
2025
Q4
$5.7M Buy
312,500
+15,000
+5% +$253K 0.04% 481
2025
Q3
$4.36M Sell
297,500
-50,100
-14% -$859K 0.03% 542
2025
Q2
$6.33M Buy
347,600
+700
+0.2% +$14.3K 0.07% 334
2025
Q1
$6.88M Buy
+346,900
New +$6M 0.07% 289

Other funds holding ADMA

Caption Management's ADMA Position: Q1 2026 in Review

Caption Management opened a new position in ADMA Biologics (ADMA) in Q1 2026: 660,000 shares worth $5.95M. The stake represents 0.03% of the portfolio and ranks #484 among its holdings. This is a return to the name: Caption Management previously reported a position in ADMA as recently as Q3 2025.

Caption Management first reported a position in ADMA in Q2 2025 and has held it in 3 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Caption Management held 660,000 shares of ADMA Biologics worth $5.95M as of Q1 2026.
  • ADMA Biologics was a new Caption Management position in Q1 2026.
  • ADMA Biologics made up 0.03% of Caption Management's portfolio in Q1 2026, its #484 holding.
  • Caption Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 3 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.